Georgina Long, BSc, PhD, MBBS, FRACP

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.

Trials are planned looking at several targeted therapies and combinations of therapies, including CDK 4/6 inhibitors, BRAF or MEK inhibitors combined with MDM2 inhibitors, and BRAF plus MEK inhibitors combined with PD-1 antibodies

Inhibition at the top of a pathway may not be the most efficacious strategy, as in the case of receptor tyrosine kinase inhibitors

Long favors approaching treatment with the immune system or with inhibitors of AKT/PI3K, CDK 4/6, or HDAC

Videos

Targeted Therapies in Development for Melanoma

Articles

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses the treatment of melanoma with emerging targeted therapies.

Georgina Long, BSc, PhD, MBBS, FRACP | Authors

Articles

Targeted Therapies in Development for Melanoma

The Treatment of Melanoma With Emerging Targeted Therapies